Over the past 50 years the short term outcome of kidney transplantation has improved significantly but maintaining the graft long term has remained a challenge (1) . Today, with the help of calcineurin inhibitors, we are able to keep the acute rejection rates low (less than 10%) (2). However, we have very few weapons in our armamentarium to identify and influence the chronic process like transplant glomerulopathy, interstitial fibrosis and tubular atrophy (1, 3) . Hence the importance of markers to identify grafts at risk for these chronic changes before they become permanent and irreversible.
The report by the GOCAR consortium published in 'The Lancet 'describes an externally validated 13 gene marker set that was expressed in biopsies 3 months after the transplantation and was independently predictive of fibrosis at 1 year (4). The investigators used biopsies at 3 months and 12 months identifying gene sets which correlated with CADI score at 3 and 12 months. From the 149 genes the investigators were able to identify 13 genes predictive of future fibrosis. This 13 gene panel consisted of genes involved in repair and regeneration pathways supporting the theory that subclinical inflammation and injury which lead to fibrosis, loss of function and ultimately organ failure.
Predicting the allografts fate with gene expression profiling is not new. Einecke et al. and Naesens et al. have previously shown the prognostic implication of gene expression profiling (5-7). The investigators in the present study have used a non-hypothesis driven approach to identify genes. Also the gene set is substantially smaller and able to predict the fibrosis at an early time post-transplant.
GOCAR scoring appears to be a very useful prognostic tool albeit with a few a limitation. All the patients in the study used calcineurin inhibitors based immunosuppression along with mycophenolate and azathioprine. The validity of the gene set for other immunosuppression has not been established. Besides the GOCAR score cannot capture the 'progressors' due to causes like delayed antibody mediated reaction and recurrent disease. Also 58 of the 159 patients in the study did not have a biopsy at 12 months which might have affected the gene profiling.
This study is an important step in identifying chronic graft failure with superior predictive value than the presently used clinical and histopathological parameters. With early identification of grafts at risk there is a potential to alter immunosuppression or identify medications which might slow, arrest and may be even reverse the chronic changes.
